Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis
- PMID: 33803489
- PMCID: PMC7967203
- DOI: 10.3390/molecules26051495
Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis
Abstract
Poor adherence to antihypertensive drug therapy is a well-recognized problem and can be assessed by mass spectrometry-based analyses of body fluids. However, contrary statements exist whether drug quantification in blood or qualitative screening in urine is more suitable. The present pilot study aimed to further elucidate the power of blood plasma drug concentrations for adherence monitoring by developing and validating a quantification procedure for nine antihypertensive drugs (amlodipine, bisoprolol, candesartan, canrenone, carvedilol, metoprolol, olmesartan, torasemide, and valsartan) in blood plasma using liquid-liquid extraction and an ultra-high-performance liquid chromatography-ion trap mass spectrometry analysis. The procedure should then be used for an adherence assessment and compared with the results of an established qualitative urine screening. Selectivity, carryover, matrix effect, accuracy, precision, dilution integrity, and stability were successfully validated, except for amlodipine. The applicability was demonstrated by analyzing 19 plasma samples containing 28 antihypertensive drugs and comparing the measured concentrations with calculated dose-dependent reference plasma concentration ranges. The interpretation of plasma concentrations was found to be more sophisticated and time-consuming than that of urine screening results, and adherence could not be assessed in two cases (10%) due to measured plasma concentrations below the lower limit of quantification. However, 14 out of 19 subjects were classified as adherent (75%) and three as nonadherent (15%), in contrast to 19 (100%) that were claimed to be adherent based on the results of the qualitative urine screening. Nevertheless, further data is needed to estimate whether plasma quantification is superior in terms of assessing adherence to antihypertensive medication.
Keywords: LC-MS/MS; adherence monitoring; antihypertensive drugs; bioanalysis; hypertension.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Reliable and easy-to-use LC-MS/MS-method for simultaneous determination of the antihypertensives metoprolol, amlodipine, canrenone and hydrochlorothiazide in patients with therapy-refractory arterial hypertension.J Pharm Biomed Anal. 2019 Feb 5;164:373-381. doi: 10.1016/j.jpba.2018.11.002. Epub 2018 Nov 5. J Pharm Biomed Anal. 2019. PMID: 30439665
-
Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence.Anal Chim Acta. 2019 Sep 6;1070:69-79. doi: 10.1016/j.aca.2019.04.026. Epub 2019 Apr 15. Anal Chim Acta. 2019. PMID: 31103169
-
Evaluation of the dose-related concentration approach in therapeutic drug monitoring of diuretics and β-blockers - drug classes with low adherence in antihypertensive therapy.Sci Rep. 2019 Oct 30;9(1):15652. doi: 10.1038/s41598-019-52164-y. Sci Rep. 2019. PMID: 31666620 Free PMC article.
-
Plasma Trough Concentrations of Antihypertensive Drugs for the Assessment of Treatment Adherence: A Meta-Analysis.Hypertension. 2021 Jan;77(1):85-93. doi: 10.1161/HYPERTENSIONAHA.120.16061. Epub 2020 Nov 30. Hypertension. 2021. PMID: 33249865 Free PMC article. Review.
-
Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan.Expert Rev Cardiovasc Ther. 2012 May;10(5):577-83. doi: 10.1586/erc.12.34. Expert Rev Cardiovasc Ther. 2012. PMID: 22651833 Review.
Cited by
-
Closing the gap - development of an analytical methodology using volumetric absorptive microsampling of finger prick blood followed by LC-HRMS/MS for adherence monitoring of antihypertensive drugs.Anal Bioanal Chem. 2023 Jan;415(1):167-177. doi: 10.1007/s00216-022-04394-9. Epub 2022 Nov 1. Anal Bioanal Chem. 2023. PMID: 36318313 Free PMC article.
-
Opportunities of Amlodipine as a Potential Candidate in the Evaluation of Drug Compliance during Antihypertensive Therapy.Medicina (Kaunas). 2023 Feb 10;59(2):340. doi: 10.3390/medicina59020340. Medicina (Kaunas). 2023. PMID: 36837543 Free PMC article.
References
-
- Ettehad D., Emdin C.A., Kiran A., Anderson S.G., Callender T., Emberson J., Chalmers J., Rodgers A., Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387:957–967. doi: 10.1016/S0140-6736(15)01225-8. - DOI - PubMed
-
- Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels—updated overview and meta-analyses of randomized trials. J. Hypertens. 2016;34:613–622. doi: 10.1097/HJH.0000000000000881. - DOI - PubMed
-
- Liu L., Wen Y., Liu K., Sun L., Lu Y., Yin Z. Simultaneous determination of a broad range of cardiovascular drugs in plasma with a simple and efficient extraction/clean up procedure and chromatography-mass spectrometry analysis. RSC Adv. 2014;4:19629–19639. doi: 10.1039/C4RA01045K. - DOI
-
- WHO Adherence to Long-Term Therapies: Evidence for Action. [(accessed on 23 February 2021)];2003 Available online: https://www.who.int/chp/knowledge/publications/adherence_report/en/
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical